{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:21:23Z","timestamp":1768566083864,"version":"3.49.0"},"posted":{"date-parts":[[2024,10,3]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe demographics, causative pathogens, hospitalization, mortality, and antimicrobial resistance of bacterial bloodstream infections (BSIs) among beneficiaries in the global U.S. Military Health System (MHS), a single-provider healthcare system with 10-year longitudinal follow-up.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Clinical and demographic data collected from the MHS Data Repository and collated with microbiological data obtained from the Defense Centers for Public Health-Portsmouth.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>12,748 MHS beneficiaries diagnosed with 15,357 bacterial BSIs (2010-2019).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Main Outcome(s) and Measure(s)<\/jats:title>\n                  <jats:p>Demographic data and diagnosis codes preceding BSI episodes and during hospitalizations were collected. Inpatient admission data identified acute clinical diagnoses, intensive care unit (ICU) admission, and mortality. BSI pathogens were evaluated for antimicrobial resistance, including difficult-to-treat resistance (DTR). Crude mortality trends were assessed.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    The decade analyzed included 15,357 BSI episodes in 12,748 patients; 6,216 patients (48.8%) were \u226565 years and 83.7% of episodes had \u22651 comorbidity (12,856 of 15,357). Approximately 29% of episodes with hospitalization required ICU admission and \u223c34% had concurrent urinary tract infections. Pathogen distribution was 53% and 47% for Gram-positive bacteria and Gram-negative bacilli (GNB), respectively. Inpatient mortality was 4.4%, and at one year was 23.4%; 0.5% (16 of 2,977) of deaths were associated with DTR GNB. Among an average 8,145,778 individuals receiving care annually in the MHS, annual rates of overall BSI, methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    , vancomycin-resistant\n                    <jats:italic>Enterococcus<\/jats:italic>\n                    spp., and DTR GNB BSI were 18.9, 1.30, 0.25, and 0.05 per 100,000 beneficiaries, respectively. Over the decade, annual mortality did not significantly increase for any pathogen and decreased by \u223c3% for lactose-fermenting GNB BSI (p=0.048).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    In the global U.S. MHS, mortality burden associated with BSI was substantial (approximately 1 in 4 dying at 1 year), relatively unchanged over a decade, and associated with older age and comorbidities. First-line treatment options remained available for 99.7% of BSIs. Population-level improvements in BSI survival might be maximally influenced by focusing on prevention, early detection, prompt antibiotics, and other novel therapies not contingent on\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Summary Box<\/jats:title>\n                  <jats:p>\n                    <jats:bold>What is already known on this topic:<\/jats:bold>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Bloodstream infections (BSIs) are associated with high healthcare burden and poor patient outcomes, including high mortality.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Modeling data based on assumptions suggest that mortality associated with antimicrobial-resistant pathogens is increasing.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>What this study adds:<\/jats:bold>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Among Military Health System (MHS) beneficiaries, overall and difficult-to-treat antimicrobial-resistant BSIs averaged an annual rate of 18.9 and 0.05 per 100,000 beneficiaries, respectively.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Over a decade, mortality did not increase annually for any BSI group, while lactose-fermenting Gram-negative BSI mortality decreased (\u223c3%) and 50% of BSIs associated with deaths at 1-year occurred &gt;42 days after BSI diagnosis.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Bacterial BSI deaths in MHS are often associated with advanced age (74% \u226565 years) and comorbidities (97% with \u22651 comorbidity), rather than absence of first-line antimicrobial treatment options.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.10.02.24314780","type":"posted-content","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T15:10:30Z","timestamp":1727968230000},"source":"Crossref","is-referenced-by-count":0,"title":["Demographics, Epidemiology, Mortality, and Difficult-To-Treat Resistance Patterns of Bacterial Bloodstream Infections in the Global United States Military Health System from 2010-2019: A Retrospective Cohort Study"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-6225","authenticated-orcid":false,"given":"Alexander C","family":"Vostal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Grance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John H","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer S","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzo","family":"Chukwuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Lanteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Leigh","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Poitras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Seliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Parmelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Mende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024100712200905000_2024.10.02.24314780v1.1","doi-asserted-by":"crossref","unstructured":"Xu J . Deaths: Final Data for 2019. National Vital Statistics Reports 2021;70.","DOI":"10.15620\/cdc:106058"},{"key":"2024100712200905000_2024.10.02.24314780v1.2","unstructured":"Torio CM , Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013: Statistical Brief #204. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD, 2006."},{"key":"2024100712200905000_2024.10.02.24314780v1.3","doi-asserted-by":"crossref","first-page":"ofaa461","DOI":"10.1093\/ofid\/ofaa461","article-title":"Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria","volume":"7","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091713"},{"key":"2024100712200905000_2024.10.02.24314780v1.5","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"2024100712200905000_2024.10.02.24314780v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/J.CMI.2019.10.031"},{"key":"2024100712200905000_2024.10.02.24314780v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"2024100712200905000_2024.10.02.24314780v1.8","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016, https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf."},{"key":"2024100712200905000_2024.10.02.24314780v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"},{"key":"2024100712200905000_2024.10.02.24314780v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000555"},{"key":"2024100712200905000_2024.10.02.24314780v1.11","unstructured":"Defense Health Agency. About the Military Health System. 2024, https:\/\/www.health.mil\/About-MHS."},{"key":"2024100712200905000_2024.10.02.24314780v1.12","unstructured":"Defense Health Agency. MHS health facilities. 2023, https:\/\/www.health.mil\/Military-Health-Topics\/MHS-Toolkits\/Media-Resources\/Media-Center\/MHS-Health-Facilities."},{"key":"2024100712200905000_2024.10.02.24314780v1.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"2024100712200905000_2024.10.02.24314780v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2024100712200905000_2024.10.02.24314780v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"2024100712200905000_2024.10.02.24314780v1.16","unstructured":"Healthcare Cost and Utility Project. Healthcare Cost and Utilization Project (HCUP) fact sheet. 2012, https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccsfactsheet.jsp."},{"key":"2024100712200905000_2024.10.02.24314780v1.17","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Sixth Informational Supplement. CLSI Doc M100-S26 Clin Lab Stand Inst. 2016."},{"key":"2024100712200905000_2024.10.02.24314780v1.18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14656566.2018.1512584","article-title":"Choosing the appropriate pharmacotherapy for multidrug-resistant Gram positive infections","volume":"19","year":"2018","journal-title":"Exp Opin Pharmacother"},{"key":"2024100712200905000_2024.10.02.24314780v1.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-022-03061-7"},{"key":"2024100712200905000_2024.10.02.24314780v1.20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/cid\/ciaa210","article-title":"Epidemiology of Escherichia coli bacteremia: a systematic literature review","volume":"72","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.21","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_104_19"},{"issue":"suppl 1","key":"2024100712200905000_2024.10.02.24314780v1.22","first-page":"s58","article-title":"Evaluating the clinical burden and mortality attributable to antibiotic resistance: the sisparity of empirical data and simple model estimations","volume":"65","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.23","doi-asserted-by":"crossref","first-page":"18262","DOI":"10.1038\/s41598-020-75158-7","article-title":"Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"2024100712200905000_2024.10.02.24314780v1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3300-0"},{"key":"2024100712200905000_2024.10.02.24314780v1.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10123-021-00184-y"},{"key":"2024100712200905000_2024.10.02.24314780v1.26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1473-3099(18)30800-4","article-title":"Attributable deaths caused by infections with antibiotic-resistant bacteria in France","volume":"19","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cid\/ciz183","article-title":"The paradigm of the shadoks and antibiotic resistance","volume":"69","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s40121-023-00827-9","article-title":"Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States Veterans Affairs medical centers, 2011-2020","volume":"12","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2024100712200905000_2024.10.02.24314780v1.29","first-page":"1063","article-title":"Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR"},{"key":"2024100712200905000_2024.10.02.24314780v1.30","unstructured":"Builder M. Antimicrobial resistance as an emerging threat to national security. 2014, https:\/\/www.atlanticcouncil.org\/wp-content\/uploads\/2015\/01\/Antimicrobial_Resistance_as_an_Emerging_Threat_to_National_Security.pdf."},{"key":"2024100712200905000_2024.10.02.24314780v1.31","doi-asserted-by":"crossref","first-page":"ofae126","DOI":"10.1093\/ofid\/ofae126","article-title":"All-cause and infection-attributable mortality amongst adults with bloodstream infection - a population-based study","volume":"11","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024100712200905000_2024.10.02.24314780v1.32","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/jac\/dkad167","article-title":"Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study","volume":"78","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024100712200905000_2024.10.02.24314780v1.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052582"},{"key":"2024100712200905000_2024.10.02.24314780v1.34","first-page":"232","article-title":"Predictive factors of in-hospital mortality in older adults with community-acquired bloodstream infection","volume":"9","year":"2020","journal-title":"J Frailty Aging"},{"key":"2024100712200905000_2024.10.02.24314780v1.35","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx091"},{"key":"2024100712200905000_2024.10.02.24314780v1.36","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12085"},{"key":"2024100712200905000_2024.10.02.24314780v1.37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcrc.2009.12.004","article-title":"Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock","volume":"25","year":"2010","journal-title":"J Critical Care"},{"key":"2024100712200905000_2024.10.02.24314780v1.38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/1469-0691.12101","article-title":"Long-term mortality following bloodstream infection","volume":"19","year":"2013","journal-title":"Clinical Microbiol Infect"},{"key":"2024100712200905000_2024.10.02.24314780v1.39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijid.2021.10.047","article-title":"Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study","volume":"114","year":"2022","journal-title":"Int J Infect Diseases"},{"key":"2024100712200905000_2024.10.02.24314780v1.40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.201510-2023OC","article-title":"Long-term mortality and major adverse cardiovascular events in sepsis survivors. a nationwide population-based study","volume":"194","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024100712200905000_2024.10.02.24314780v1.41","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.mayocp.2020.07.023","article-title":"Antibiotics approved for marketing in populations specifically excluded from premarketing trials, 1999-2018","volume":"95","year":"2020","journal-title":"Mayo Clin Proc"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.10.02.24314780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:13:50Z","timestamp":1768508030000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.10.02.24314780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2024.10.02.24314780","relation":{},"subject":[],"published":{"date-parts":[[2024,10,3]]},"subtype":"preprint"}}